Pipeline Database & Screener

Over 1500 entries in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data.

N.B. The short ratio is the number of shares sold short divided by the average daily volume, also known as the number of "days to cover".

Pipeline data are updated at the end of each trading day. Click on the date for the source of the catalyst. Financial data updated each evening.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates. 

Showing 423 companies
Screener
Sort
Stage
Market Cap
Price
Short ratio
Relative Volume
Price to book
FDA Calendar
Company
Price
Change
Market Cap
Outstanding Shares
Short Ratio
Updated
$39.21
+0.7  +1.82%
$1.72B
43,976,000
3.99
04/20/2017
Tap to view 6 drugs
Drug Indication Stage News
Annexin V-128 Early Breast Cancer Phase 2 Phase 2 initiated September 2016
Annexin V-128 Rheumatoid arthritis and ankylosing spondylitis Phase 1/2 Ongoing
Apoptosis Necrosis Phase 2 Phase 2 initiated September 2016
Lutathera Inoperable progressive midgut NETs CRL CRL issued December 21, 2016. Noted March 23, 2017 that NDA to be resubmitted mid-2017.
Somakit-TATE Neuroendocrine tumor diagnosis Approved Approved June 1, 2016.
Somakit-TOC Neuroendocrine cancers Positive opinion by EMA released in October 2016.
$66.32
+0.39  +0.59%
$105.55B
1,591,540,000
4.90
05/10/2017
Tap to view 29 drugs
Drug Indication Stage News
ABBV-8E12 Progressive supranuclear palsy (PSP) Phase 2 Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: May 2019
ABBV-8E12 Alzheimer's disease Phase 2 Phase 2 initiation announced January 25, 2017. Estimated Primary Completion Date: April 2020.
ABT-414 Recurrent glioblastoma (rGBM) Phase 1 Phase 1 data at ASCO. Oral Abstract 2003. June 4, 2017.
ABT-494 Psoriatic Arthritis Phase 3 Phase 3 trial to commence 2017.
ABT-494 Crohn’s Disease Phase 2b Phase 2 positive data at DDW Meeting May 9, 2017. Phase 3 trial to be initiated later in 2017.
ABT-494 Atopic Dermatitis Phase 2b Phase 2b data due 2017.
ABT-494 - SELECT-BEYOND Rheumatoid arthritis Phase 3 Phase 3 top-line data due summer 2017. Estimate Aug 31 is last possible date.
ABT-494 - SELECT-NEXT Rheumatoid arthritis Phase 3 Phase 3 top-line data due June 2017.
Elagolix Uterine Fibroids Phase 3 Phase 3 initiated in January 2016. Data due late 2017.
Elagolix Endometriosis Phase 3 First Phase 3 trial met both co-primary endpoints - Jan 2015. Data from second Phase 3 released February 2016 also met endpoints. NDA Filing due 3Q 2017.
Glecaprevir/Pibrentasvir (G/P) Hepatitis C virus (HCV) PDUFA priority review Priority review granted February 2, 2017. No PDUFA date supplied. Estimate August 2, 2017.
Ibrutinib Relapsed or refractory MCL mantle cell lymphoma Approved Approved November 13, 2013.
Imbruvica Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy Approved Approved February 12, 2014.
Imbruvica Deletion 17p Approved Approved July 19, 2014.
IMBRUVICA Waldenström’s Macroglobulinemia Approved Approved January 29, 2015 - PCYC
Imbruvica Second-line Chronic graft-versus-host disease (GVHD) PDUFA priority review sNDA filing announced April 4, 2017. Assuming priority review would render a PDUFA date of September 4, 2017. Awaiting confirmation of official PDUFA date.
Imbruvica Marginal zone lymphoma Approved sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Imbruvica - PHOENIX First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 interim data possibly due 2H 2017.
Risankizumab Crohn’s Disease Phase 3 Phase 3 trial to commence 1H 2017.
Risankizumab Psoriasis Phase 3 Phase 3 data due by the end of 2017.
Risankizumab Psoriatic Arthritis Phase 2b Phase 2b data due 2017.
Rova-T First-line small cell lung cancer (SCLC) maintenance Phase 3 Phase 3 trial to commence 2017.
Rova-T (TRINITY) Third-line Small Cell Lung Cancer Phase 2 Phase 2 pivotal data due 2017.
Veliparib Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC) Phase 3 Phase 3 trial did not meet primary endpoints - April 19, 2017.
Venclexta Follicular lymphoma (FL) Phase 3 Phase 3 trial to commence 2017.
Venclexta First-line Diffuse large B-cell lymphoma (DLBCL) Phase 3 Phase 3 trial to commence 2017.
Venclexta (MURANO) Relapsed or refractory Chronic Lymphocytic Leukemia (CLL) Phase 3 Phase 3 data due 2017 as per 1Q earnings call.
Venetoclax Relapsed or refractory multiple myeloma Phase 3 Phase 3 trial initiated July 2016. Data due 2019.
VIEKIRA PAK HCV - genotype 1 Approved Approved December 19, 2014.
$5.70
-0.2  -3.39%
$229.45M
40,255,000
16.42
05/12/2017
Tap to view 3 drugs
Drug Indication Stage News
ABO-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 2 Phase 2 enrollment commenced September 2016.
ABO-102 Sanfilippo syndrome type A (MPS IIIA) Phase 1/2 Phase 1/2 updated data released May 12, 2017.
EB-101 Recessive dystrophic epidermolysis bullosa (RDEB) Phase 1/2 Phase 1/2 updated data presented at Society for Investigative Dermatology (SID) April 28, 2017.
$2.35
-0.1  -4.08%
$21.46M
9,130,000
3.50
05/15/2017
Tap to view 1 drug
Drug Indication Stage News
Gencaro - GENETIC-AF trial Chronic Heart Failure Phase 2b Phase 2b interim analysis due September 2017.
$3.50
-0.15  -4.12%
$192.58M
55,024,000
8.76
05/04/2017
Tap to view 3 drugs
Drug Indication Stage News
AB-423 (MAD) Hepatitis B (HBV) Phase 2 Phase 2 trial to be initiated 2H 2017.
ARB-1467 Hepatitis B (HBV) Phase 2 Phase 2 Cohort 4 data due 3Q 2017.
TKM-PLK1 Hepatocellular carcinoma (HCC) Phase 1/2 Phase 1/2 data released July 2016. Intends to explore partnership opportunities to enable further study
$26.27
-1.1  -3.98%
$3.21B
122,046,000
10.10
05/10/2017
Tap to view 5 drugs
Drug Indication Stage News
Pimavanserin Adjunctive treatment in patients with negative symptoms of schizophrenia Phase 2 Phase 2 initiated November 2016.
Pimavanserin Adjunctive treatment of schizophrenia Phase 3 Phase 3 initiated November 2016.
Pimavanserin Parkinson’s disease psychosis (PDP) Approved Approved April 29 2016
Pimavanserin Alzheimer’s disease psychosis Phase 2 Phase 2 top-line data released December 20, 2016. Primary endpoint met. Key secondary endpoint missed. Phase 3 trial to be initiated 2H 2017.
Pimavanserin - SERENE Alzheimer’s disease agitation Phase 2 Phase 2 trial initiated October 2016.
$4.15
+0.01  +0.24%
$567.40M
136,723,000
7.20
05/04/2017
Tap to view 4 drugs
Drug Indication Stage News
ACH-4471 C3 glomerulopathy (C3G) Phase 2 trial to be initiated 2H 2017.
ACH-4471 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 initiation announced April 6, 2017. Interim data due 2Q 2017.
JNJ-4178 Hepatitis C (HCV) Phase 2a Phase 2a ongoing. Updated data presented at EASL April 22, 2017.
JNJ-4178 - OMEGA-1 Hepatitis C (HCV) Phase 2b Phase 2b trial initiation announced November 30, 2016. Data due 2H 2017.
$8.91
-0.05  -0.57%
$507.18M
56,922,000
13.23
03/17/2017
Tap to view 4 drugs
Drug Indication Stage News
ACI-24 (anti-Abeta vaccine) Alzheimer’s disease Phase 1/2 Phase 1/2 ongoing. IPO September 23, 2016. Decision on future trials due within next few months - as of March 17, 2017.
ACI-35 (anti-tau vaccine) Alzheimer’s disease Phase 1b Phase 2 trial to commence 2017. IPO September 23, 2016.
Crenezumab - CREAD 1 Alzheimer’s disease Phase 3 Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 2 Alzheimer’s disease Phase 3 Second Phase 3 trial initiation announced February 28, 2017.
$14.55
-0.6  -3.96%
$680.33M
46,758,000
5.25
04/29/2017
Tap to view 5 drugs
Drug Indication Stage News
Ampyra Improve walking in patients with multiple sclerosis Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
CVT-301 OFF episodes of Parkinson’s disease (PD) Phase 3 Phase 3 data released February 9, 2017 - primary endpoint met. NDA filing due by the end of 2Q 2017.
CVT-427 Migraine Phase 2 Phase 2 to be initiated by the end of 2017.
Dalfampridine Post stroke deficits Phase 3 Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Tozadenant Parkinson’s disease (PD) Phase 3 Phase 3 data due 1Q 2018.
$25.21
+0.23  +0.92%
$673.94M
26,733,000
6.90
05/10/2017
Tap to view 4 drugs
Drug Indication Stage News
A-101 Seborrheic keratosis (SK) PDUFA PDUFA date is December 24, 2017
A-101 Common warts (verruca vulgaris) Phase 2 Phase 2 data released August 2016. Plans to initiate two Phase 2 trials in mid-2017.
ATI-50001 Alopecia totalis and alopecia universalis Phase 2 Phase 2 trial to be initiated 2H 2017.
ATI-50002 Patchy alopecia areata Phase 2 Phase 2 trial to be initiated 2H 2017.
$2.55
-0.1  -3.77%
$115.72M
45,380,000
18.78
05/08/2017
Tap to view 3 drugs
Drug Indication Stage News
ARX-04 (SAP302) Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury Phase 3 Phase 3 data released August 15 2016
ARX-04 (SAP303) Moderate-to-severe acute pain following a surgical procedure PDUFA PDUFA date October 12, 2017. Advisory Committee meeting planned summer of 2017.
Zalviso Post-operative pain following open abdominal surgery and hip or knee replacement surgery Phase 3 CRL Jul 26 2014. Additional clinical trial required. Phase 3 trial initiated September 2016. Data due mid-2017.
$1.25
-0.01  -0.79%
$13.39M
10,712,000
1.97
03/30/2017
Tap to view 1 drug
Drug Indication Stage News
CaPre (TRIFECTA trial) Hypertriglyceridemia Phase 3 Phase 3 to be initiated 2H 2017.
$5.30
-0.02  -0.38%
$495.53M
93,496,000
0.73
11/21/2016
Tap to view 5 drugs
Drug Indication Stage News
NY-ESO T-cell therapy Synovial sarcoma - cancer Phase 3 Phase 3 to be initiated 2H 2017.
NY-ESO T-cell therapy Ovarian cancer Phase 1/2 Further trials planned for 2H 2016
NY-ESO T-cell therapy Myxoid round cell liposarcoma (MRCLS) Phase 3 Pivotal trial placed on clinical hold due to non-safety issues. Hold released November 2016. Envisage initiation 4Q 2016 or 1Q 2017
NY-ESO T-cell therapy Myeloma Phase 1/2 Further trials planned for 1H 2017.
NY-ESO T-cell therapy Non-small cell lung cancer (NSCLC) Phase 1/2 Phase 1/2 initiated November 2015. Data are due 2017.
$1.12
-0.01  -0.88%
$30.87M
27,562,000
1.97
02/22/2017
Tap to view 3 drugs
Drug Indication Stage News
MDX (Metadoxine Extended Release (MG01CI)) Adult ADHD Phase 3 Phase 3 data released January 17, 2017 - failed to meet primary endpoint.
MDX (Metadoxine Extended Release (MG01CI)) Pediatric ADHD Phase 2 Phase 2b data released March 2015. Secondary cognitive measures did not produce statistically significant results.
MDX (Metadoxine Extended Release (MG01CI)) Fragile X Syndrome Phase 2 Phase 2 trial did not meet endpoints - June 2015.
$3.53
-0.03  -0.84%
$45.49M
12,886,000
2.47
05/22/2017
Tap to view 1 drug
Drug Indication Stage News
RI-002 Primary Immune Deficiency Diseases CRL CRL issued July 29 2016. Third-party manufacturing issues cited.
$3.80
-0.2  -5%
$86.01M
22,634,000
6.53
02/25/2017
Tap to view 3 drugs
$15.55
-0.46  -2.87%
$347.68M
22,359,000
29.44
02/26/2017
Tap to view 3 drugs
Drug Indication Stage News
ADS-5102 Multiple sclerosis (MS) Phase 2 Phase 2 data released early June 2016. Evaluating Phase 3 pathway.
ADS-5102 Levodopa-Induced Dyskinesia PDUFA PDUFA date August 24, 2017.
Namzaric Moderate to severe dementia of the Alzheimer's type. Approved Approved December, 24 2014.
$10.20
+0.05  +0.49%
$713.11M
69,913,000
21.23
05/02/2017
Tap to view 5 drugs
Drug Indication Stage News
CRS-207 and GVAX Pancreas - ECLIPSE trial Pancreatic cancer Phase 2b Phase 2b primary endpoint not met - May 2016
CRS-207 and GVAX Pancreas and nivolumab - STELLAR trial Pancreatic cancer Phase 2b Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
CRS-207 with anti-PD1 Gastric cancer Phase 2 Phase 2 trial to be initiated 2Q 2017.
CRS-207 with anti-PD1 Mesothelioma - cancer Phase 2 Phase 2 trial to be initiated 2Q 2017 with early data due 2H 2017.
Epacadostat and CRS-207 - SEASCAPE Ovarian cancer Phase 1/2 Phase 1/2 dosing initiated March 2016.Partial clinical hold announced October 24, 2016. Hold released November 21, 2016.
$2.65
-0.1  -3.64%
$113.60M
42,869,000
2.87
05/10/2017
Tap to view 2 drugs
Drug Indication Stage News
ADVM-043 Alpha-1 Antitrypsin (A1AT) Deficiency Phase 1/2 Phase 1/2 trial to be initiated 4Q 2017.
AVA-101 Wet age-related macular degeneration (Wet-AMD) Phase 2a Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
$8.70
-0.46  -5.02%
$350.57M
40,295,000
12.06
02/06/2017
Tap to view 7 drugs
Drug Indication Stage News
ADXS-HER2 HER2-driven malignancies - cancer Phase 1b Phase 1b ongoing.
ADXS-PSA and Keytruda Castrate-resistant prostate cancer Phase 1/2 Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Enrollment to be completed by end of 2017.
Axalimogene filolisbac Cervical cancer Phase 3 Phase 3 trial to be initiated 2H 2017.
Axalimogene filolisbac Anal cancer (FAWCETT) Phase 2 Phase 2 initiated June 2016. Preliminary update due 2H 2017.
Axalimogene filolisbac - AIM2CERV Trial High-risk, locally advanced cervical cancer Phase 3 Announced Phase 3 first patient dosed - February 6, 2017.
Axalimogene filolisbac - GOG 0265 study Cervical cancer Phase 2 Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac + durvalumab Recurrent or refractory HPV-associated cervical cancer and head & neck cancer Phase 1/2 Phase 1/2 updated data due 2H 2017.
$0.96
+0.07  +7.87%
$13.76M
14,333,000
2.93
05/01/2017
Tap to view 2 drugs
Drug Indication Stage News
Macimorelin Acetate - Macrilen Adult Growth Deficiency Phase 3 Phase 3 data released January 4, 2017 - trial failed. Announced March 30, 2017 intention to file NDA 3Q 2017.
Zoptrex Endometrial cancer Phase 3 Phase 3 trial did not meet primary endpoint - May 1, 2017.
$2.35
-0.05  -2.08%
$103.25M
43,938,000
2.96
05/17/2017
Tap to view 2 drugs
Drug Indication Stage News
AFM13 Hodgkin Lymphoma - Cancer Phase 2 Phase 2a update due 2H 2017 with full data due 2019.
AFM13 with Keytruda Hodgkin Lymphoma - Cancer Phase 1b Phase 1b update 2H 2017.
$3.50
-0.06  -1.69%
$346.91M
99,118,000
8.52
04/20/2017
Tap to view 3 drugs
Drug Indication Stage News
AGEN2034 Solid tumors Phase 1/2 Phase 1/2 initiation announced April 20, 2017.
INCAGN1876 Solid tumors - cancer Phase 1/2 Phase 1/2 trial commenced June 2016
INCAGN1949 Solid tumors - cancer Phase 1/2 Phase 1/2 trial initiation announced November 30, 2016.
$47.46
+0.22  +0.47%
$2.29B
48,204,000
13.19
05/18/2017
Tap to view 6 drugs
Drug Indication Stage News
AG-120 IDH1m Relapsed/Refractory AML - cancer NDA Filing NDA filing due by end of 2017.
AG-120 IDH1 mutant positive cholangiocarcinoma - cancer Phase 3 Phase 3 initiated December 2016.
AG-120 and VIDAZA - AGILE Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer Phase 3 Phase 3 to be initiated 2Q 2017.
AG-348 Pyruvate kinase deficiency Phase 2 Phase 2 first data released at EHA meeting June 2016. Updated data due at EHA June 24, 2017 with further data due 2H 2017.
Enasidenib (AG-221) Advanced hematologic malignancies with an IDH2 mutation PDUFA priority review PDUFA date August 30, 2017 under priority review.
Enasidenib (AG-221) - IDHENTIFY Refractory Acute myeloid leukemia (AML) - cancer Phase 3 Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of April 2017.
$4.43
-0.32  -6.74%
$59.59M
13,452,000
0.34
04/10/2017
Tap to view 2 drugs
Drug Indication Stage News
AEB1102 Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS) Phase 1 Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
AEB1102 Arginase I deficiency Phase 1/2 Phase 1 top-line data presented March 23, 2017.
$224.36
+0.2  +0.09%
$75.36B
335,867,000
2.69
04/27/2017
Tap to view 23 drugs
Drug Indication Stage News
ABICIPAR Diabetic macular edema (DME) Phase 3 Phase 3 trial to be initiated 2H 2017.
ABICIPAR Age-related macular degeneration (AMD) Phase 3 Phase 3 data due 2018.
ABP 215 Biosimilar candidate to Avastin (bevacizumab) PDUFA BLA filed November 15, 2016. BsUFA date September 14, 2017.
ATOGEPANT Prophylaxis (migraine) Phase 2b Phase 2b top-line data due 2018.
AVYCAZ (ceftazidime and avibactam) Complicated Urinary Tract Infections (cUTI) Approved sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Bimatoprost Androgenic Alopecia Phase 3 Phase 3 enrollment to be completed 2H 2017.
Botox Depression Phase 2 Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Brazikumab Crohn's disease Phase 2b Phase 2b data due 2018.
Brimo DDS Atrophic Age-related macular degeneration (AMD) Phase 2 Phase 2 top-line data due 2H 2017.
Cariprazine Major depressive disorder (MDD) Phase 3 Phase 3 data due 2018.
Cariprazine Schizophrenia/ Negative symptoms PDUFA sNDA filing acceptance announced March 8, 2017. PDUFA date not noted.
Cenicriviroc (CVC) Nonalcoholic steatohepatitis (NASH) Phase 3 Phase 3 to be initiated 2H 2017.
Cortisol Analog Dry Eye disease Phase 3 Phase 3 trial to be initiated 2H 2017.
ESMYA (Venus II) Uterine Fibroids Phase 3 Phase 3 data released January 18, 2017 - endpoints met. NDA filing due 2H 2017.
JUVÉDERM VOLLURE Correction of moderate to severe facial wrinkles and folds Approved Approval announced March 20, 2017.
Liletta Prevention of pregnancy PDUFA sNDA accepted January 4, 2017. PDUFA estimate September 4, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults Chronic idiopathic constipation (CIC) Approved sNDA approval announced January 26, 2017.
Oxymetazoline HCl cream 1.0% Facial Erythema (Redness) Associated with Rosacea Approved Approved January 19, 2017.
RAPASTINEL Major depressive disorder (MDD) Phase 3 Phase 3 initiated October 2016. Data due early 2019.
RELAMORELIN Diabetic Gastroparesis Phase 3 Phase 3 to be initiated 2H 2017.
RORγt agonist Psoriasis Phase 2b Phase 2b trial to be initiated 2H 2017.
Sarecycline Severe acne vulgaris Phase 3 Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
UBROGEPANT Acute (migraine) Phase 3 Phase 3 initiated July 2016. Data due 2018.
$3.46
-0.02  -0.57%
$99.67M
28,806,000
6.26
04/11/2017
Tap to view 1 drug
$5.45
+0.1  +1.87%
$98.51M
18,076,000
2.57
05/11/2017
Tap to view 2 drugs
Drug Indication Stage News
AAV Gene Therapy CNGB3 Achromatopsia Phase 1/2 Phase 1/2 continues to enroll - May 2017.
rAAV-hRS1 X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 data due summer of 2017.
$18.26
+1  +5.79%
$919.25M
50,342,000
10.54
05/11/2017
Tap to view 2 drugs
$22.08
-1.57  -6.64%
$791.63M
35,853,000
3.96
05/08/2017
Tap to view 3 drugs
Drug Indication Stage News
C-Scape Complicated urinary tract infections (cUTI) due to multi-drug resistant (MDR) pathogens Phase 3 Phase 3 trial to be initiated 2Q 2017.
Plazomicin - CARE Serious bacterial infections due to carbapenem-resistant Enterobacteriaceae (CRE) NDA Filing Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
Plazomicin - EPIC trial Complicated urinary tract infections (cUTI) Phase 3 Phase 3 data released December 12, 2016 - primary endpoint met. NDA filing due 2H 2017.
$13.85
-0.39  -2.74%
$253.46M
18,300,000
5.66
11/21/2016
Tap to view 2 drugs
Drug Indication Stage News
Vadadustat - INNO2VATE Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD) Phase 3 Phase 3 initiated August 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
Vadadustat - PRO2TECT Non-dialysis patients with anemia related to CKD (NDD-CKD) Phase 3 Phase 3 initiated January 2016. NDA filing pending positive data due 2019. Estimate data release mid-2019.
$6.69
+0.18  +2.76%
$78.78M
11,776,000
2.88
04/24/2017
Tap to view 1 drug
Drug Indication Stage News
Coversin Paroxysmal nocturnal hemoglobinuria (PNH) Phase 2 Phase 2 interim data released April 24, 2017. Phase 3 program to commence 4Q 2017 with initial data due 1Q 2019.
$19.14
-1.63  -7.85%
$120.43M
6,292,000
0.94
05/16/2017
Tap to view 1 drug
Drug Indication Stage News
A4250 Progressive familial intrahepatic cholestasis (PFIC) Phase 3 Phase 3 planned for 2H 2017.
$17.05
+0.15  +0.89%
$859.49M
50,410,000
15.29
05/27/2017
Tap to view 3 drugs
Drug Indication Stage News
ALD403 Chronic Migraine Phase 2b Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data released July 2016.
ALD403 - PROMISE 1 Frequent episodic migraine Phase 3 Phase 3 PROMISE 1 topline data due 2Q 2017.
ALD403 - PROMISE 2 Frequent episodic migraine Phase 3 Phase 3 PROMISE 2 initiation announced November 28, 2016. Data due 1H 2018.
$4.75
+0.12  +2.7%
$29.66M
6,245,000
1.73
05/15/2017
Tap to view 4 drugs
Drug Indication Stage News
ADX-102 Dry eye syndrome Phase 2a Phase 2a data due 3Q 2017.
ADX-102 Allergic conjunctivitis Phase 2b Phase 2b enrollment initiation announced February 7, 2017. Data due June 2017.
ADX-102 Noninfectious anterior uveitis Phase 3 Phase 3 trial initiation announced April 27, 2017 with data due 2H 2018.
ADX-102 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 3 trial initial data due 2H 2018.
$1.46
+0  +0%
$94.70M
64,862,000
1.57
02/26/2017
Tap to view 1 drug
Drug Indication Stage News
Iluvien Diabetic macular edema Approved CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
$69.50
-0.47  -0.67%
$5.99B
86,190,000
12.01
05/05/2017
Tap to view 9 drugs
Drug Indication Stage News
ALN-CC5 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 1/2 Phase 1/2 initial data presented at ASH 2016.
ALN-GO1 Primary Hyperoxaluria Type 1 (PH1) Phase 1/2 Phase 1/2 initiated March 2016. Initial data released September 2016.
ALN-HBV Chronic hepatitis B virus (HBV) Phase 1/2 Phase 1/2 trial initiated July 2016. Data are due mid 2017
ALN-TTRsc02 ATTR amyloidosis Phase 1 Development plan to be confirmed following APOLLO data release in mid 2017.
Fitusiran (ATLAS) Hemophilia Phase 3 Phase 3 program to be initiated 3Q 2017.
Givosiran Acute hepatic porphyrias Phase 1 Phase 1 additional data due June 2017 with a Phase 3 trial to be initiated in late 2017.
Inclisiran Hypercholesterolemia Phase 3 Phase 3 trial design agreed to by FDA - noted April 26, 2017.
Patisiran APOLLO Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR Phase 3 Phase 3 data due mid-2017.
Revusiran ENDEAVOUR ATTR in patients with familial amyloidotic cardiomyopathy (FAC) Phase 3 Phase 3 trial discontinued October 2016.
$98.50
-2.58  -2.55%
$22.12B
224,556,000
1.71
04/28/2017
Tap to view 6 drugs
Drug Indication Stage News
ALXN1101 Molybdenum cofactor deficiency (MoCD) Type A Phase 2/3 Phase 2/3 enrolling.
ALXN1210 atypical Hemolytic Uremic Syndrome (aHUS) Phase 3 Phase 3 enrollment to be completed 2017; expects to initiate a Phase 3 trial in pediatric patients 2Q 2017.
ALXN1210 Paroxysmal nocturnal hemoglobinuria (PNH) Phase 3 Phase 3 enrollment commenced 4Q 2016. Enrollment to be completed 2017.
Eculizumab Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Phase 3 Phase 3 enrollment to be completed in 2017.
Eculizumab Refractory generalized myasthenia gravis (gMG) PDUFA (sBLA) PDUFA date October 23, 2017.
SBC-103 MPS IIIB Phase 1/2 Phase 1/2 ongoing. No additional studies planned.
$18.20
-1.05  -5.45%
$637.82M
35,045,000
7.22
04/17/2017
Tap to view 3 drugs
Drug Indication Stage News
Feraheme Adults with iron deficiency anemia (IDA) Phase 3 Phase 3 trial to be completed estimated 1H 2017. sNDA due mid 2017.
Makena - auto injector Reduce the risk of preterm birth in women with a singleton pregnancy sNDA Filing sNDA filing announced April 17, 2017. PDUFA date estimated October 17, 2017 assuming 6-month priority review.
Rekynda Hypoactive sexual desire disorder (HSDD) NDA Filing NDA filing due early 2018.
AMGN Amgen Inc.
$155.43
+0.83  +0.54%
$114.30B
735,399,000
1.76
05/22/2017
Tap to view 15 drugs
Drug Indication Stage News
ABP 710 REMICADE biosimilar - rheumatoid arthritis Phase 3 Phase 3 enrolling.
ABP 798 RITUXAN biosimilar - non-Hodgkin lymphoma Phase 3 Phase 3 enrolling. Estimate data 1H 2018 using clinicaltrials.gov data.
ABP 980 Herceptin biosimilar Phase 3 BLA filing due 2017.
BLINCYTO Ph+ R/R ALL PDUFA priority review PDUFA date under priority review August 14, 2017.
CHS-1701 Pegfilgrastim biosimilar PDUFA BLA submission announced August 9, 2016. PDUFA date estimate June 9, 2017.
CNP 520 Alzheimer’s Disease Phase 2/3 Phase 2/3 ongoing.
Corlanor Chronic Heart Failure Approved Approved April 15, 2015.
Erenumab Migraine BLA Filing Phase 3 trial met primary endpoint September 2016. BLA filing announced May 18, 2017.
EVENITY (Romosozumab) Osteoporosis PDUFA PDUFA date July 19, 2017. However, likely to be delayed due to safety data from ARCH trial released May 22, 2017.
KYPROLIS (ARROW) Multiple Myeloma Phase 3 Phase 3 trial initiated June 2015.
KYPROLIS (ENDEAVOR) Relapsed Multiple Myeloma Phase 3 Phase 3 trial met PFS endpoint - March 2015. Announced February 28, 2017 that interim analysis met secondary endpoint of overall survival (OS).
Omecamtiv mecarbil GALACTIC-HF Acute heart failure Phase 3 Phase 3 commencement announced December 1, 2016.
Parsabiv Secondary hyperparathyroidism (SHPT) Approved Approved February 7, 2017.
Repatha Cardiovascular disease Phase 3 Phase 3 cardiovascular outcomes study data released March 17, 2017 - endpoints met but down on expectations.
XGEVA Multiple Myeloma PDUFA sBLA filing announced April 4, 2017. Standard 10-month review would render a PDUFA date on or about February 4, 2017. Awaiting confirmation.
$15.47
-0.03  -0.19%
$707.55M
45,737,000
5.30
02/23/2017
Tap to view 3 drugs
Drug Indication Stage News
Albuterol DPI Asthma Phase 2b
Naloxone Intranasal Opioid overdose CRL CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol) Asthma CRL CRL issued December 27, 2016.
$3.05
+0.05  +1.67%
$825.62M
270,695,000
3.25
05/03/2017
Tap to view 1 drug
Drug Indication Stage News
Vascepa REDUCE-IT outcomes trial High Triglycerides With Mixed Dyslipidemia Interim analysis announced September 12, 2016 - trial to proceed.Second interim analysis due late 3Q 2017. Final data due mid-2018.
$26.70
+0.28  +1.06%
$541.18M
20,269,000
2.50
05/11/2017
Tap to view 3 drugs
Drug Indication Stage News
ANB020 Moderate-to-severe adult atopic dermatitis Phase 2 Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
ANB020 Severe adult eosinophilic asthma Phase 2a Phase 2a data due 1H 2018.
ANB020 Severe adult peanut allergy Phase 2a Phase 2a trial initiated 1Q 2017 with data due 2H 2017.
$46.45
+0.1  +0.22%
$680.68M
14,654,000
8.83
05/25/2017
Tap to view 2 drugs
Drug Indication Stage News
Cingal Osteoarthritis Phase 3 Additional Phase 3 trial commenced enrollment - May 25 2017. Trial to be completed in 2018.
Monovisc Osteoarthritis Approved Approved Feb 2014
$1.74
+0.04  +2.35%
$17.53M
10,076,000
2.27
05/10/2017
Tap to view 4 drugs
Drug Indication Stage News
Blisibimod IgA nephropathy Phase 2 Phase 2 primary endpoint not met following interim analysis. Trial to continue. Data due 3Q 2017.
Blisibimod Lupus Phase 3 Phase 3 trial did not meet endpoints - November 10, 2016.
Sollpura - RESULT Exocrine pancreatic insufficiency Phase 3 Phase 3 data due end of 2017 or early 2018.
Sollpura (liprotamase) Cystic fibrosis who suffer from exocrine pancreatic insufficiency Phase 3 Top-line data released December 27, 2016 - missed primary endpoint.
$0.76
-0.05  -5.58%
$5.04M
6,627,000
4.81
01/12/2017
Tap to view 1 drug
Drug Indication Stage News
AB-SA01 Chronic rhinosinusitis (CRS) Phase 1 Phase 2 to be initiated 2H 2017.
$0.96
-0.01  -1.03%
$7.43M
7,741,000
3.56
05/11/2017
Tap to view 2 drugs
Drug Indication Stage News
RayVa Secondary Raynaud's Phenomenon Phase 2b Phase 2b planned - seeking partnership.
Vitaros Erectile dysfunction NDA Filing NDA resubmission planned for 3Q 2017.
$14.04
-0.09  -0.64%
$328.86M
23,423,000
20.38
05/09/2017
Tap to view 3 drugs
Drug Indication Stage News
AQX-1125 FLAGSHIP Chronic obstructive pulmonary disease (COPD) Phase 2 Phase 2 trail failed - July 2015
AQX-1125 KINSHIP Atopic dermatitis (AD) Phase 2 Phase 2 failed to demonstrate efficacy November 2015
AQX-1125 LEADERSHIP Bladder pain syndrome/interstitial cystitis (BPS/IC). Phase 3 Phase 2 trial did not meet endpoints - June 2015 but positive secondary endpoint data - August 2015. Phase 3 trial commenced September 2016. Reported March 9, 2017 that enrollment has been slower than expected. Data now due 2018.
$1.29
-0.03  -2.27%
$19.09M
14,800,000
1.44
02/27/2017
Tap to view 2 drugs
Drug Indication Stage News
Pulmaquin - ORBIT-3 and ORBIT-4 Non-cystic fibrosis bronchiectasis (non-CF BE). Phase 3 Phase 3 data released December 1, 2016. One of two trials met primary endpoint.
Sumavel Migraine Approved Approval granted July 16, 2009.
$4.95
-0.4  -7.48%
$234.56M
47,386,000
7.20
05/12/2017
Tap to view 5 drugs
Drug Indication Stage News
RDX227675 Hyperkalemia Phase 3 Phase 3 trial initiation announced January 3, 2017.
RDX7675 Hyperkalemia Phase 2 Onset of action trial data due 3Q 2017.
Tenapanor Hyperphosphatemia in end-stage renal disease (ESRD) patients Phase 3 Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial to be initiated mid-2017.
Tenapanor (T3MPO-1) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.
Tenapanor (T3MPO-2) Constipation-predominant irritable bowel syndrome (IBS-C) Phase 3 Phase 3 data due early 4Q 2017. Estimate November 15, 2017 as latest possible date using company guidance of "early 4Q".
$0.40
-0.03  -4.76%
$16.74M
41,351,000
2.50
05/10/2017
Tap to view 4 drugs
ARGX argenx SE
$21.41
+0.79  +3.83%
$430.90M
20,126,000
0.00
05/26/2017
Tap to view 4 drugs
Drug Indication Stage News
ARGX-110 Relapsed/refractory cutaneous T-cell lymphoma (CTCL) Phase 2 Phase 2 interim data due by the end of 2017 with top-line data due by the end of 2018.
ARGX-110 Acute myeloid leukemia (AML) Phase 1/2 Phase 1/2 interim data due by the end of 2017.
ARGX-113 Immune thrombocytopenia (ITP) Phase 2 Phase 2 data due 2H 2018.
ARGX-113 Myasthenia gravis (MG) Phase 2 Phase 2 data due 1Q 2018.
$1.37
-0.04  -2.84%
$90.21M
65,845,000
3.71
02/27/2017
Tap to view 2 drugs
Drug Indication Stage News
VIMOVO Gastric ulcers Approved Approved April 30, 2010.
YOSPRALA (PA32540/PA8140) Secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers Approved Approval announced September 15, 2016.
$1.36
-0.02  -1.45%
$431.71M
317,435,000
4.76
05/10/2017
Tap to view 8 drugs
Drug Indication Stage News
APD371 Pain associated with Crohn's disease Phase 2 Phase 2 enrolling as of May 2017.
Etrasimod Primary biliary cholangitis (PBC) Phase 2 Phase 2 to be initiated 2017.
Etrasimod Pyoderma gangrenosum (PG) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Dermatological extraintestinal manifestations (EIM) in patients with inflammatory bowel disease (IBD) Phase 2 Phase 2 trial initiated March 2017.
Etrasimod Ulcerative colitis Phase 2 Phase 2 data due by the end of 2017.
Lorcaserin Obesity Approved Approved June 27, 2012.
Lorcaserin Smoking cessation Phase 2 Phase 2 initiated March 2014. Data released Nov 2014
Ralinepag Pulmonary Arterial Hypertension Phase 2 Phase 2 data due July 2017.
$1.17
-0.01  -0.85%
$83.24M
71,146,000
2.07
05/03/2017
Tap to view 3 drugs
Drug Indication Stage News
ARQ 087 intrahepatic cholangiocarcinoma (iCCA) Phase 1/2 Phase 2 enrollment completed. Poster discussion at ASCO June 3, 2017. Phase 3 trial planned for 3Q 2017.
ARQ 092 Overgrowth Diseases Phase 1/2 Phase 1/2 trial has commenced enrollment - May 4, 2017.
Tivantinib (ARQ 197) METIV-HCC trial Previously treated Inoperable Hepatocellular Carcinoma cancer Phase 3 Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
$8.27
-0.08  -0.84%
$1.41B
170,800,000
4.49
05/10/2017
Tap to view 7 drugs
Drug Indication Stage News
ARRY 797 LMNA A/C-related dilated cardiomyopathy (DCM) Phase 2 Phase 2 data presented at the European Society of Cardiology on August 30, 2016. Phase 3 trial to be initiated in summer 2017.
ARRY-520 (Filanesib) Refractory Multiple Myeloma Cancer Phase 2 Phase 2 interim data due 2016 but no plans to advance program
Binimetinib - COLUMBUS BRAF mutant melanoma cancer Phase 3 Phase 3 data released September 26, 2016 met primary endpoint. Data from Part 2 portion of trial due released May 9, 2017. NDA filing due June or July 2017.
Binimetinib - MILO Recurrent low-grade serous ovarian cancer (LGSOC) Phase 3 Phase 3 trial discontinued April 2016
Binimetinib (NEMO) NRAS melanoma - cancer Phase 3 PDUFA date originally set for June 30, 2017. Announed withdrawl of NDA filing - March 20, 2017.
Encorafenib and cetuximab - BEACON CRC BRAF-Mutant Colorectal Cancer Phase 3 Phase 3 initiated June 2016. SPA announced September 2016. Randomization part of trial now enrolling. Expects to present early data from the safety lead-in later in 2017..
Selumetinib - SELECT-1 Differentiated thyroid cancer Phase 3 Phase 3 trial did not meet its primary endpoint - August 2016
$1.57
-0.03  -1.87%
$117.39M
74,772,000
13.41
11/30/2016
Tap to view 3 drugs
Drug Indication Stage News
ARC-520 injection in combination with entecavir or tenofovir Chronic Hepititis B (HBV) Phase 2 Announced that development will be discontinued - November 29, 2016.
ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Announced that development will be discontinued - November 29, 2016.
ARC-AAT Alpha-1 antitrypsin deficiency (AATD) Phase 2 Announced that development will be discontinued - November 29, 2016.
$25.40
+0.05  +0.2%
$440.59M
17,346,000
4.55
07/25/2016
Tap to view 1 drug
Drug Indication Stage News
VEN 307 (diltiazem cream) Anal fissures Phase 3 Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
$25.03
-0.32  -1.26%
$811.50M
32,421,000
8.80
05/23/2017
Tap to view 1 drug
Drug Indication Stage News
TransCon Growth hormone deficiency in children Phase 3 Phase 3 initiated August 2016. Enrollment to be completed 4Q 2017.
$1.44
-0.01  -0.69%
$160.30M
111,316,000
3.64
11/21/2016
Tap to view 2 drugs
$1.41
+0  +0%
$78.69M
55,807,000
2.60
11/23/2016
Tap to view 2 drugs
Drug Indication Stage News
Actimab-A Acute Myeloid Leukemia (AML) Phase 2 Phase 2 initiated September 2016. Interim analysis due mid-2017.
Iomab-B Hematopoietic Stem Cells Transplantation Phase 3 Phase 3 initiated June 2016. Data due 1H 2018.
$0.47
-0.01  -1.03%
$1.76M
3,786,000
0.64
01/10/2017
Tap to view 1 drug
Drug Indication Stage News
Fulvestrant Cuctal carcinoma in situ(DCIS) - invasive breast cancer Phase 2 Phase 2 enrollment to be completed by August 2017.
$14.40
-0.1  -0.69%
$419.17M
29,109,000
11.97
05/04/2017
Tap to view 5 drugs
Drug Indication Stage News
ATA 129 - ALLELE Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT) Phase 3 Phase 3 trial planned for 2H 2017.
ATA 129 - MATCH Epstein-Barr virus (EBV-PTLD) after after hematopoietic cell transplant (HCT) Phase 3 Phase 3 trial planned for 2H 2017.
ATA129 and KEYTRUDA Nasopharyngeal carcinoma (NPC) Phase 1/2 Phase 1/2 trial to be initiated 2018.
CMV-CTL Refractory CMV Chorioretinitis or Meningoencephalitis Phase 2 Phase 2 data released at ASH 2015. Expects to meet with FDA during 4Q 2016 to discuss further development
PINTA 745 Protein-energy wasting Phase 2 Phase 2 endpoint not met December 2015
$2.55
+0  +0%
$395.80M
155,214,000
2.39
05/09/2017
Tap to view 4 drugs
Drug Indication Stage News
Anturol Overactive bladder Approved Approved December 8, 2011.
Makena - auto injector Preterm birth sNDA filing announced April 17, 2017. PDUFA date October 17, 2017 assuming 6-month priority review.
OTREXUP Rheumatoid arthritis (RA) Approved Approved Oct 14, 2013.
VIBEX QuickShot Testosterone deficiency PDUFA PDUFA date October 20, 2017.
$6.59
-0.33  -4.77%
$352.09M
53,428,000
0.88
05/15/2017
Tap to view 2 drugs
Drug Indication Stage News
Voclosporin - AURION trial Lupus Phase 2 48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURORA Lupus Phase 3 Phase 3 trial initiation announced May 15, 2017.
$9.90
-0.04  -0.4%
$409.62M
41,376,000
2.58
02/26/2017
Tap to view 5 drugs
Drug Indication Stage News
Akovaz Hypotension Approved Announced approval May 2 2016
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved June 3, 2013.
Bloxiverz (neostigmine methylsulfate) Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery Approved Approved Jun 3 2013
Micropump Sodium Oxybate Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy Phase 3 Phase 3 SPA agreed on - October 2016. Initiation of dosing announced December 16, 2016.
VAZCULEP (phenylephrine hydrochloride) Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia Approved Approved June 30 2014.
$0.79
-0.02  -1.76%
$86.63M
110,362,000
3.84
05/04/2017
Tap to view 3 drugs
Drug Indication Stage News
Ficlatuzumab EGFR-mutated Non-small cell lung cancer (NSCLC) Phase 2 Announced September 12, 2016 that its Phase 2 trial has been discontinued
TIVO-3 - tivozanib Third line treatment of patients with renal cell cancer Phase 3 Phase 3 enrollment to be completed June 2017. Futility analysis due mid-2017. Top-line data due 1Q 2018 (Poster session at ASCO June 4, 2017). Abstract TPS4600.
Tivozanib + Opdivo Renal cell cancer (RCC) Phase 1/2 Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial due to be completed 2Q 2017.
$0.50
+0  +0.78%
$19.28M
38,649,000
0.92
05/04/2017
Tap to view 4 drugs
Drug Indication Stage News
BTA074 5% topical gel Condyloma Phase 2 Phase 2 enrollment to be completed 2H 2017 with data due 1H 2018.
BTA585 Respiratory syncytial virus (RSV) Phase 2a Phase 2a data released February 1, 2017 - primary endpoint not met.
Laninamivir Octanoate - IGLOO Adults with symptomatic influenza A or B infection Phase 2 Phase 2 initiated Jun 2013. Topline data did not meet the primary endpoint - July 2014
Vapendavir - SPIRITUS trial Human rhinovirus (HRV) Phase 2b Phase 2b top-line data released February 13, 2017 - primary endpoint not met.
$5.94
+0.13  +2.24%
$245.77M
41,376,000
8.16
05/10/2017
Tap to view 2 drugs
Drug Indication Stage News
ANAVEX 2-73 Rett syndrome Phase 2 Phase 2 planned for 2017.
ANAVEX 2-73 Mild to moderate Alzheimer’s disease Phase 2a Phase 2a 12-month data released December 8, 2016. Trial is ongoing. Additional Phase 2/3 trial planned for 2017.
$76.69
+4.13  +5.71%
$2.13B
27,794,000
9.52
05/11/2017
Tap to view 1 drug
$21.71
-0.96  -4.24%
$2.15B
99,161,000
11.40
02/22/2017
Tap to view 4 drugs
Drug Indication Stage News
Intepirdine - HEADWAY-DLB Dementia with Lewy bodies (DLB) Phase 2b Phase 2b data due 4Q 2017
Intepirdine - MINDSET Alzheimer's disease Phase 3 Phase 3 data are due 3Q 2017.
Nelotanserin DLB patients experiencing REM Behavior Disorder (RBD) Phase 2 Phase 2 data due 2H 2017.
Nelotanserin Visual hallucinations in subjects with Lewy body dementia Phase 2 Phase 2 preliminary data released February 13, 2017. Primary endpoint hit, secondary endpoints missed. Full study to be completed mid-2017. Phase 3 trial to be initiated 2H 2017.
$3.95
-0.15  -3.66%
$93.24M
23,605,000
4.16
05/09/2017
Tap to view 5 drugs
Drug Indication Stage News
AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 Phase 3 initiation contingent upon resources.
AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017.
AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
$34.34
+0.07  +0.2%
$86.95B
2,532,000,000
6.76
05/12/2017
Tap to view 32 drugs
Drug Indication Stage News
Acalabrutinib - ACE-LY-004 Relapsed or Refractory Mantle Cell Lymphoma Phase 2 Phase 2 data 2Q or mid 2017.
Anifrolumab Lupus Phase 3 Phase 3 data due 2018.
AZD3293 Early Alzheimer's disease Phase 3 Phase 3 data due 2019.
Benralizumab COPD Phase 3 Phase 3 data due 2018.
Benralizumab Severe, uncontrolled asthma Phase 3 Guided in November for a regulatory filing by the end of 2016.
Brilinta (THEMIS) Type 2 Diabetes Phase 3 Phase 3 data due 1Q 2018.
Bydureon Type 2 Diabetes Phase 3 Phase 3 Cardiovascular Outcome trial data due 3Q 2017.
Dapa-HF Heart failure Phase 3 Phase 3 trial commenced 1Q 2017.
Durvalumab (ADJUVANT) Adjuvant Non-small cell lung cancer (NSCLC) Phase 3 Phase 3 data due 2020.
Durvalumab (PACIFIC) Lung cancer Phase 3 Phase 3 interim analysis released May 12, 2017 - PFS primary endpoint already met. OS endpoint to be assessed.
Durvalumab +/- tremelimumab (ARCTIC) Lung cancer Phase 3 Phase 3 data 4Q 2017.
Durvalumab +/- tremelimumab (DANUBE) Bladder cancer Phase 3 Phase 3 data due 2018.
Durvalumab +/- tremelimumab (EAGLE) Head & neck cancer Phase 3 Phase 3 data due 2018.
Durvalumab +/- tremelimumab (KESTREL) Head & neck cancer Phase 3 Phase 3 data due 2H 2017.
Durvalumab +/- tremelimumab (MYSTIC) Lung cancer Phase 3 Phase 3 PFS data mid-2017.
Durvalumab +/- tremelimumab (NEPTUNE) Lung cancer Phase 3 Phase 3 data due 2018.
Farxiga - DECLARE Cardiovascular Outcomes Phase 3 Phase 3 data due 2019.
Faslodex Breast cancer Phase 3 NDA filed 4Q 2016.
Lynparza First-line ovarian cancer Phase 3 Phase 3 data due 2H 2017.
Lynparza Breast cancer Phase 3 Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017. Abstract LBA4.
Lynparza - SOLO 2 Second-line ovarian cancer PDUFA priority review Data presented March 14, 2017 showed significant PFS benefit. PDUFA date under priority review 3Q 2017. Estimate September 28, 2017 assuming 6-month review.
Moxetumomab Cancer - leukaemia Phase 3 Phase 3 data due 2H 2017.
PT010 Chronic obstructive pulmonary disease (COPD) Phase 3 Phase 3 data due 2018.
Roxadustat - ANDES Anaemia Phase 3 Phase 3 data due 2018.
Saxagliptin and dapagliflozin Type-2 diabetes Approved Approval announced February 28, 2017.
Selumetinib - ASTRA Thyroid cancer Phase 3 Phase 3 data due 2018.
Tagrisso Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC) Approved Approval announced March 31, 2017.
Tagrisso First-line lung cancer Phase 3 Phase 3 data due 2H 2017.
Tralokinumab (STRATOS1) Severe, uncontrolled asthma Phase 3 Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS2) Severe, uncontrolled asthma Phase 3 Phase 3 data due 2H 2017.
Urothelial carcinoma - Bladder cancer Bladder cancer Approved BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
ZS-9 Hyperkalaemia CRL Second CRL issued March 17, 2017.
$3.75
+0.08  +2.18%
$36.12M
9,631,000
0.50
04/15/2017
Tap to view 1 drug
Drug Indication Stage News
MS1819-SD Exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis (CP) Phase 2 Announced December 21, 2016 that Phase 2 enrollment has commenced. Trial completion due 3Q 2017.
$4.04
-0.03  -0.74%
$75.50M
18,687,000
3.24
03/30/2017
Tap to view 1 drug
Drug Indication Stage News
NurOwn Amytrophic lateral sclerosis (ALS) Phase 3 Phase 2 data released July 2016. Phase 3 trial to be initiated 2Q 2017.
$6.73
+1.6  +31.19%
$541.23M
80,420,000
3.60
05/25/2017
Tap to view 3 drugs
Drug Indication Stage News
BCX4161 - OPuS-2 Hereditary angioedema Phase 2b Phase 2b data released February 2016 - primary endpoint not met
BCX7353 - APeX-1 Reduce or eliminate attacks in HAE patients Phase 2 Phase 2 interim data released February 27, 2017. Top-line data released May 25, 2017.
Peramivir - Study 303 INFLUENZA ACUTE Approved Approved Dec 22 2014
$2.20
+0  +0%
$121.72M
55,325,000
10.62
02/26/2017
Tap to view 3 drugs
Drug Indication Stage News
BEMA Buprenorphine Pain Approved Approved October 26, 2015.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL Opioid dependence Approved Approved June 6, 2014.
Clonidine gel Painful diabetic neuropathy (PDN) Phase 2b Phase 2b data released December 13, 2016 - primary endpoints not met.
$37.46
-0.94  -2.46%
$1.49B
39,725,000
11.85
04/21/2017
Tap to view 3 drugs
Drug Indication Stage News
BGB-3111 Relapsed or refractory mantle cell lymphoma (MCL) Phase 3 Phase 3 dosing of China based trial announced March 2, 2017.
BGB-3111 Waldenström’s macroglobulinemia Phase 3 Phase 3 trial initiation announced January 25, 2017.
BGB-A317 and BGB-290 Solid tumors Phase 1/2 Phase 1/2 preliminary data to be presented at ASCO June 5, 2017. Abstract 3013.
$22.97
+1.12  +5.17%
$300.63M
13,088,000
0.00
05/06/2017
Tap to view 3 drugs
Drug Indication Stage News
BHV-0223 Amyotrophic lateral sclerosis (ALS) Bioequivalence study planned for 2017. NDA to be filed using 505(b)(2) regulatory pathway.
BHV-4157 Trigriluzole Spinocerebellar Ataxia Phase 2/3 Phase 2b/3 enrollment commenced December 2016. Phase 2 top-line data due 1Q 2018.
Rimegepant Migraine Phase 3 Phase 3 trials to be initiated 2H 2017 with top-line data due 1Q 2018.
$252.97
-0.36  -0.15%
$53.66B
212,115,000
1.52
05/15/2017
Tap to view 17 drugs
Drug Indication Stage News
Aducanumab (Aβ mAb) - EMERGE Alzheimer’s disease Phase 3 Phase 3 enrollment to be completed mid-2018.
Aducanumab (Aβ mAb) - ENGAGE Alzheimer’s disease Phase 3 Phase 3 enrollment to be completed mid-2018.
BAN2401 (Aβ mAb) Alzheimer’s disease Phase 2 Phase 2 data due by the end of 2017.
BG00011 (STX-100) Idiopathic pulmonary fibrosis (IPF) Phase 2 Phase 2 to be completed 2017.
BIIB059 (anti-BDCA2) Lupus Phase 2 Phase 2 dosing commenced October 2016.
BIIB074 (Nav1.7 inhibitor) Trigeminal Neuralgia Phase 3 Phase 3 to be initiated in 2018.
BMS-986168 - Anti Tau Progressive supranuclear palsy (PSP) Phase 2 Phase 2 initiated April 2017.
BMS-986168 - Anti Tau Alzheimer’s disease Phase 2 Phase 2 planned.
CIRARA (intravenous glyburide) Ischemic stroke Phase 3 Phase 3 ready to be initiated. Acquired from Remedy Pharmaceuticals May 15, 2017.
Dapirolizumab pegol (anti-CD40L) Lupus Phase 2 Phase 2 ongoing.
Elenbecestat (E2609) - (MissionAD1) Alzheimer’s disease Phase 3 Phase 3 dosing commenced December 2016.
Elenbecestat (E2609) - (MissionAD2) Alzheimer’s disease Phase 3 Phase 3 dosing commenced December 2016.
Natalizumab (α4-integrin inhibitor) Acute ischemic stroke Phase 2b Phase 2b enrollment to be completed 2017.
Opicinumab (anti-LINGO) Multiple sclerosis (MS) Phase 2b Phase 2b to be initiated 4Q 2017.
Raxatrigine - BIIB074 (Nav1.7 inhibitor) Painful Lumbosacral Radiculopathy (PLSR) Phase 2 Phase 2 initiated 2016. Data due in 2018.
Raxatrigine - BIIB074 (Nav1.7 inhibitor) Erythromelagia Phase 2 Phase 2 topline data showed no statistically significant treatment effect for primary and secondary endpoints - 1Q 2016.
XLRS Gene Therapy X-linked retinoschisis (XLRS) Phase 1/2 Phase 1/2 data due mid-2017.
$12.19
-0.29  -2.32%
$403.53M
33,103,000
3.75
04/15/2017
Tap to view 4 drugs
Drug Indication Stage News
BPX-401 Hematological cancers that express the CD19 antigen Phase 1/2 Phase 1/2 planned 2H 2016
BPX-501 - BP-004 Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer Phase 1/2 Phase 1/2 update February 22, 2017.
BPX-601 Pancreatic cancer Phase 1 Phase 2 trial initiation of dosing announced February 21, 2017.
BPX-701 PRAME (preferentially-expressed antigen in melanoma) -expressing melanoma, sarcomas and neuroblastoma cancer Phase 1/2 Phase 1/2 commenced March 2017.
$1.38
-0.01  -0.72%
$44.21M
32,039,000
2.09
05/22/2017
Tap to view 3 drugs
Drug Indication Stage News
INOpulse delivery device Pulmonary Hypertension associated with Idiopathic Pulmonary Fibrosis (PH-IPF) Phase 2 Phase 2 initiated May 2016. Data presented at American Thoracic Society (ATS) Conference, May 21 2017. Phase 2b planned.
INOpulse delivery device Pulmonary Arterial Hypertension (PAH) Phase 3 Phase 3 commenced enrollment June 2016. Interim analysis due 4Q 2017 with top-line data due mid-2018.
INOpulse delivery device Pulmonary Hypertension associated with COPD (PH-COPD) Phase 2 Phase 2 initiated 3Q 2016. Data due mid-2017.
$0.85
-0.01  -1.17%
$52.51M
61,782,000
0.37
05/25/2017
Tap to view 6 drugs
Drug Indication Stage News
BL-7010 Gluten sensitivity Phase 1/2 Development plans to be released by early 2017.
BL-8040 Consolidation treatment for AML cancer patients Phase 2b Phase 2b initiated August 2015. Interim analysis due in 2018, with top-line results expected in 2019.
BL-8040 Mobilization and collection of bone marrow stem cells Phase 2 Phase 2 trial initiated March 2016. Partial data released March 20, 2017 with topline results by the end of 2017 with Phase 2/3 trial to be initiated 2H 2017.
BL-8040 Acute myeloid leukemia (AML) cancer relapsed and refractory Phase 2 Phase 2 data released March 2016. Full set of data presented September 8, 2016
BL-8040 in combination with KEYTRUDA Pancreatic cancer Phase 2 Phase 2a trial initiation announced January 17, 2017.
BL-8040 in combination with KEYTRUDA - COMBAT trial Pancreatic cancer Phase 2 Phase 2 initiated September 2016. Partial data due 2H 2017. Full data due 2H 2018.
$79.80
+0.05  +0.06%
$3.27B
40,950,000
8.80
05/18/2017
Tap to view 6 drugs
Drug Indication Stage News
bb2121 Relapsed/refractory multiple myeloma Phase 1 Phase 1 interim data released November 30, 2016 - 78% ORR. Pivotal trial to be initiated 2017. Updated data at ASCO June 5, 2017. Abstract 3010
Lenti-D - Starbeam Childhood cerebral adrenoleukodystrophy (CCALD) Phase 2/3 Phase 2/3 trial initiated October 2013. Interim data released at AAN Conference April 20, 2016. Full data due by the end of 2017.
LentiGlobin - HGB-204 β-Thalassemia Phase 1/2 Updated data presented at ASH December 5, 2016.
LentiGlobin - HGB-206 Sickle disease Phase 1/2 Update at ASH 2016. Further data due at ASH 2017. Exact date TBC.
LentiGlobin - HGB-207 Northstar-2 non-β0/β0 transfusion-dependent thalassemia (TDT) Phase 3 Noted on December 14, 2016 that Phase 3 dosing has commenced. Early data due at EHA June 25, 2017.
LentiGlobin - HGB-212 TDT and the β0/β0genotype Phase 3 Phase 3 trial to be initiated 2H 2017.
$87.33
-0.7  -0.8%
$15.24B
174,490,000
6.44
05/04/2017
Tap to view 7 drugs
Drug Indication Stage News
BMN 270 Hemophilia A Phase 1/2 Phase 1/2 update due at International Society of Thrombosis and Haemostasis (ISTH) 2017 Congress, July 8-13, 2017. Phase 2b trial to be initiated 3Q 2017.
Cerliponase alfa Batten Disease Approved PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Kyndrisa Duchenne Muscular Dystrophy (DMD) CRL CRL issued January 14, 2016.
Pegvaliase Phenylketonuria (PKU) Phase 3 Phase 3 data released March 2016. Primary endpoint hit. Key secondary endpoint missed. BLA filing to be filed 2Q 2017.
Reveglucosidase alfa (BMN 701) Pompe Disease Phase 2 Program terminated June 2016
Vimizim (GALNS) (MPS IVA) Morquio A Syndrome Approved Approved February 14, 2014.
Vosoritide Achondroplasia Phase 3 Phase 3 trial initiation announced December 12, 2016.
$54.39
+0.56  +1.06%
$89.60B
1,647,434,000
2.81
05/24/2017
Tap to view 24 drugs
Drug Indication Stage News
CM - 067 Opdivo in combination with Yervoy Melanoma Phase 3 Phase 3 first overall survival (OS) positive data released April 3, 2017
CM-040 – Opdivo PDUFA priority review PDUFA date under priority review September 24, 2017.
CM-078 – Opdivo Second-line Non-small cell lung cancer (NSCLC) Phase 3 Phase 3 data due 1H 2018.
CM-142 – Opdivo (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC) PDUFA priority review PDUFA date under priority review August 2, 2017.
CM-142 – Opdivo (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC) PDUFA priority review PDUFA date under priority review August 2, 2017.
CM-142 – Opdivo (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC) PDUFA priority review PDUFA date under priority review August 2, 2017.
CM-143 – Opdivo Second-line Glioblastoma (GBM) cancer Phase 3 Phase 3 data released April 3, 2017 - primary endpoint not met.
CM-214 – Opdivo + Yervoy First-line Renal cell carcinoma (RCC) Phase 3 Phase 3 data due 2H 2017.
CM-227 – Opdivo + Yervoy First-line Non-small cell lung cancer (NSCLC) Phase 3 Phase 3 data due 1H 2018.
CM-238 – Opdivo (Adjuvant) Melanoma Phase 3 Phase 3 data due 2H 2018.
CM-331– Opdivo Second-line Small cell lung cancer (SCLC) Phase 3 Phase 3 data due 1H 2018.
CM-451 – Opdivo + Yervoy First-line Small cell lung cancer (SCLC) Phase 3 Phase 3 data due 1H 2018.
CM-459 – Opdivo First-line Hepatocellular carcinoma (HCC) - cancer Phase 3 Phase 3 data due 2H 2017.
CM-511 – Opdivo + Yervoy First-line Melanoma Phase 3 Phase 3 data due 2Q or 3Q 2017.
CM-548 - Opdivo+SOC First-line Glioblastoma (GBM) cancer Phase 2 Phase 2 data due 1H 2018.
CM-568 - Opdivo + Yervoy First-line Non-small cell lung cancer (NSCLC) Phase 2 Phase 2 data due 2H 2018 – 1H 2019.
CM-602 – Opdivo + Elo + SOC Myeloma Phase 3 Phase 3 data due 2H 2018.
CM-651 – Opdivo + Yervoy First-line Head and Neck Cancer Phase 3